StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.1
  1. Startseite
  2. /Verbindung

Sumatriptan Succinate

HCID 59772
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
103628-48-4
Standard-SMILES
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O
InChIKey
PORMUFZNYQJOEI-UHFFFAOYSA-N
Summenformel
C18H27N3O6S
Durchschnittliche Molmasse
413,5 g/mol
Monoisotopische Masse
413,16205676

Überblick

Sumatriptan succinate is a succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatment of migraine with or without aura in adults. It has a role as a serotonergic agonist and a vasoconstrictor agent. It contains a sumatriptan(1+).

Namen und Bezeichner

Bevorzugter Name
Sumatriptan Succinate
IUPAC
butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
Englischer Name
Sumatriptan succinate
Summenformel
C18H27N3O6S
Molmasse
413.48848

Namen und Synonyme

SUMATRIPTAN SUCCINATE103628-48-4Sumavel DoseProAlsumaOnzetra XsailImitrex StatdoseGR 43175CZembrace SymTouchSumatriptan GalpharmSumatriptan (as succinate)GR-43175CNSC-760362
Weitere Namen anzeigen
SuMitrexgr43175cSumatriptan succinatSuccinate Sumatriptanmethanesulfonamide(1:1)SumatriptanSuccinate>Penehyclidine Impurity 9SUMATRIPTANSUCCINATE(1:1)SuMatriptan Succinate, EP
J8BDZ68989CHEBI:64359DTXSID60145966ZecuityImigran subjectMigraleve ultraMigraine PackImigran 50

Datenbank-Bezeichner

CAS
103628-48-4
PubChem CID
59772
DTXSID
DTXSID60145966

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

Polarare Oberfläche (TPSA)
148 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
9
Schwere Atome
28
Formalladung
0
Komplexität
498

Experimentelle und physikochemische Eigenschaften

Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Triptans; Vasoconstrictor Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt
165 · 165-166°C
storage temp.
-20 °C · -20°C
Löslichkeit
2 O: · H2O: >20mg/mL
Aggregatzustand
solid
Farbe
white to off-white
Merck
14 · 14,8997
BCS Class
3 · 3
Major Application
pharmaceutical (small molecule)
InChI
1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
InChIKey
PORMUFZNYQJOEI-UHFFFAOYSA-N
SMILES

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H318 (79.6%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

P203, P264+P265, P273, P280, P305+P354+P338, P317, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 54 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationSumatriptan succinate: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesEye Dam. 1 (79.6%)

Toxikologische Informationen

Exposure RoutesSubcutaneous, Oral, Nasal, Transdermal
Toxicity Summary · 1 Eintrag

The 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Sumatriptan also blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve.

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme. Route of Elimination: Only 3% of the dose is excreted in the urine as unchanged sumatriptan; 42% of the dose is excreted as the major metabolite, the indole acetic acid analogue of sumatriptan. Half Life: 2.5 hours

FDA Pharmacological Classification · 2 Einträge

SUMATRIPTAN SUCCINATE

Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]; Serotonin 1d Receptor Agonists [MoA]; Serotonin 1b Receptor Agonists [MoA]

MeSH Pharmacological Classification · 2 Einträge

Drugs used to cause constriction of the blood vessels.

Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.

Verwendung und Herstellung

UsesFor the treatment of migraine attacks with or without aura.
Anwendungen · 2 Einträge

BeschreibungSumatriptan succinate is a highly selective 5HT1-like receptor agonist introduced as a new treatment for migraine. It is indicated for the acute relief of migraine and cluster headache. Oral administration is reported to be free of substantial side effects. The compound appears to be a significant advance over the use of ergotamine and other agents in the treatment of migraine.

VerwendenSumatriptan Succinate is a selective 5-HT1B/1D-receptor agonist with anticonvulsant properties (1,2). Sumatriptan Succinate is used for migraine relief (2).

Vor- und nachgelagerte Produkte

Zugehörige Reaktionen

2
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1625661
HRID 1625661als Eduktuspto-grants-2014_07
Reaktionsgleichung von HRID 1797389
HRID 1797389als Produktuspto-grants-2006_04

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEMBL
CHEMBL1201150
ChEBI
CHEBI:64359
UNII
J8BDZ68989
EC Number
600-463-4
OC(=O)CCC(O)=O.CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
CAS Datenbank
103628 · 103628-48-4(CAS DataBase Reference)
Signs and SymptomsSymptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sumatriptan succinate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
3
ridadr
3077
hs_code
29350090
RTECS-Nr.
EJ9940000
risk_code
36/37/38-41
hazard_code
Xi
safety_code
26-36-39
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Aquatic Chronic 3Repr. 2

Vorgelagerte Rohstoffe

4-Hydrazino-N-Methyl Benzene Methane Sulphonamide Hydrochloride

Nachgelagerte Produkte

Sumatriptan
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatm nt of migraine with or without aura in adults.